Gilead Sciences, Inc. (GILD)

Gilead Sciences' stock reached an all-time high of $128.70 on November 20, 2025, and was at $121.10 on January 9, 2026, up from $89.94 on January 13, 2025. Over the last six months, GILD shares returned 5.5%, while the S&P 500 gained 10.1%. Key events include Q3 2025 earnings exceeding estimates, strong Veklury sales, the successful launch of Yeztugo, analyst upgrades, pipeline expansion through licensing Assembly Biosciences' programs, and insider selling activity.

Demand for Gilead Sciences' products can exhibit seasonality, particularly for certain drugs. Veklury sales showed a strong seasonality-driven increase in Q3 2025. Biktarvy sales were sequentially down in Q1 2025, reflecting typical first-quarter seasonality. Descovy also experienced typical seasonal inventory dynamics in Q1, although overall sales increased due to higher average realized price and demand.

Gilead Sciences is a research-based biopharmaceutical company focused on transforming and simplifying care for people with life-threatening illnesses globally. Historically, Gilead has been a leader in antiviral therapies, particularly for HIV/AIDS and viral hepatitis, and has strategically expanded into oncology and inflammation through acquisitions. Major products include HIV/AIDS treatments like Biktarvy, Descovy, and Genvoya; liver disease treatments like Epclusa and Harvoni; the COVID-19 antiviral Veklury; oncology products like Trodelvy and Yescarta; and other products like AmBisome and Tamiflu.

Gilead Sciences has a significant global presence with its headquarters in Foster City, California. It operates through subsidiaries and offices in North America (United States, Canada, Mexico), Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russia, Spain, Sweden, Switzerland, United Kingdom), Asia-Pacific (Japan, Australia, Singapore, China, Hong Kong, India, Korea, Taiwan), Latin America (Brazil, Mexico, Argentina, Colombia), the Middle East (Israel, Saudi Arabia, Türkiye, United Arab Emirates), and Africa (South Africa).

Gilead Sciences maintains a strong brand reputation as a leading biopharmaceutical company known for its contributions to treating life-threatening diseases, particularly in virology and oncology. The successful launch of new drugs like Yeztugo and positive analyst sentiment regarding its HIV franchise and pipeline expansion likely contribute positively to its brand image. Challenges in its oncology franchise or declining sales in certain areas like Veklury could present reputational considerations.

Gilead Sciences is predominantly owned by institutional investors, holding between 72.97% and 88% of the company's shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Fmr Llc, State Street Corp, Capital World Investors, Dodge & Cox, Capital Research Global Investors, and Geode Capital Management, Llc. Individual investors hold approximately 12% to 27.37% of the company's stock, while insider ownership is less than 1%.